CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.3%

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) dropped 0.3% on Friday . The stock traded as low as $54.64 and last traded at $55.52. Approximately 345,464 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 1,741,560 shares. The stock had previously closed at $55.67.

Wall Street Analyst Weigh In

Several research firms recently commented on CRSP. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Robert W. Baird boosted their price objective on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a "neutral" rating in a report on Thursday, May 9th. Mizuho lifted their target price on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a "buy" rating in a research report on Wednesday, March 6th. Morgan Stanley boosted their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an "underweight" rating in a research note on Monday, February 26th. Finally, Oppenheimer dropped their price target on CRISPR Therapeutics from $102.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, May 10th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $73.93.

CRISPR Therapeutics Trading Up 1.0 %

The business's 50 day moving average is $62.11 and its two-hundred day moving average is $65.21. The company has a market cap of $4.77 billion, a PE ratio of -20.67 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $25.53 million. The business's revenue was down 99.5% compared to the same quarter last year. During the same period last year, the company posted ($0.67) EPS. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.64 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 20,000 shares of the firm's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $72.48, for a total value of $1,449,600.00. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares of the company's stock, valued at $15,084,682.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other CRISPR Therapeutics news, CFO Raju Prasad sold 3,524 shares of the company's stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the sale, the chief financial officer now directly owns 6,476 shares in the company, valued at $470,740.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.48, for a total value of $1,449,600.00. Following the completion of the transaction, the chief executive officer now owns 208,122 shares of the company's stock, valued at approximately $15,084,682.56. The disclosure for this sale can be found here. Insiders have sold a total of 63,992 shares of company stock valued at $4,525,135 in the last quarter. 4.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Jump Financial LLC increased its stake in CRISPR Therapeutics by 194.7% in the 3rd quarter. Jump Financial LLC now owns 33,307 shares of the company's stock worth $1,512,000 after buying an additional 22,006 shares during the period. Invesco Ltd. increased its stake in shares of CRISPR Therapeutics by 1.5% during the third quarter. Invesco Ltd. now owns 136,123 shares of the company's stock valued at $6,179,000 after buying an additional 2,061 shares during the period. ARK Investment Management LLC raised its holdings in shares of CRISPR Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company's stock valued at $534,360,000 after acquiring an additional 1,372,986 shares in the last quarter. Prime Capital Investment Advisors LLC purchased a new stake in CRISPR Therapeutics in the fourth quarter worth about $206,000. Finally, Baker Chad R grew its holdings in CRISPR Therapeutics by 89.1% during the 4th quarter. Baker Chad R now owns 98,520 shares of the company's stock worth $6,167,000 after acquiring an additional 46,420 shares in the last quarter. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.